Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare Biotechnology
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix Reports Q3 2019 Results

PR Newswire November 1, 2019

Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma

PR Newswire September 18, 2019

Pulmatrix Receives US Patent Covering iSPERSE(TM) Formulations for Pulmazole Program

PR Newswire August 19, 2019

Pulmatrix Reports Q2 2019 Results

PR Newswire August 5, 2019

Pulmatrix Activates Sites for Pulmazole Phase 2 Clinical Study

PR Newswire July 9, 2019

Pulmatrix Reports Q1 2019 Results

PR Newswire May 15, 2019

Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole(TM)

PR Newswire April 15, 2019

Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering

PR Newswire April 8, 2019

Thinking about buying stock in Cronos Group Inc., Facebook Inc., InspireMD Inc., Pulmatrix Inc., or Sangamo Therapeutics?

PR Newswire April 2, 2019

Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole

PR Newswire April 1, 2019

Pulmatrix to Participate in Upcoming Investor Conferences

PR Newswire March 14, 2019

Pulmatrix Regains NASDAQ Compliance

PR Newswire March 12, 2019

Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline

PR Newswire February 19, 2019

Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs

PR Newswire February 12, 2019

Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market

PR Newswire February 8, 2019

Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study

PR Newswire February 7, 2019

Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1

PR Newswire February 6, 2019

Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split

PR Newswire February 5, 2019

Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock

PR Newswire February 5, 2019

Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock

PR Newswire January 31, 2019